Last reviewed · How we verify
Radium bromatum (RADIUM)
Radium bromatum works by emitting ionizing radiation that damages cancer cells, preventing them from growing and dividing.
Radium bromatum, also known as radium, is a small molecule drug developed by Bayer Healthcare. Although it was FDA approved in 2016, its target, drug class, and approved indications are unknown. Radium bromatum is currently off-patent, with no active Orange Book patents. As a result, there are no generic manufacturers. Despite its commercial status, key safety considerations are not publicly available.
At a glance
| Generic name | RADIUM |
|---|---|
| Sponsor | Bayer Hlthcare |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2016 |
Mechanism of action
Imagine your body's cells are like a city with a mayor. Cancer cells are like a corrupt mayor who makes bad decisions and causes problems. Radium bromatum is like a special kind of police officer that uses radiation to arrest the corrupt mayor and restore order to the city.
Approved indications
- Malignant tumor of prostate
Common side effects
Key clinical trials
- Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (PHASE2)
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (PHASE1,PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (PHASE2)
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (PHASE2)
- Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (PHASE1)
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) (PHASE4)
- Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer (PHASE2)
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radium bromatum CI brief — competitive landscape report
- Radium bromatum updates RSS · CI watch RSS
- Bayer Hlthcare portfolio CI